Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average Price Target from Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $11.71.

A number of research firms have recently issued reports on HUMA. HC Wainwright began coverage on Humacyte in a report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price objective for the company. Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a report on Friday, June 27th. D. Boral Capital restated a "buy" rating and set a $25.00 target price on shares of Humacyte in a report on Wednesday. Finally, Benchmark dropped their target price on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. Columbia Advisory Partners LLC bought a new stake in shares of Humacyte in the 1st quarter worth approximately $27,000. Hamilton Lane Advisors LLC bought a new stake in shares of Humacyte in the 1st quarter worth approximately $37,000. Letko Brosseau & Associates Inc. bought a new position in Humacyte in the 1st quarter worth $42,000. Pallas Capital Advisors LLC bought a new position in Humacyte in the 2nd quarter worth $42,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Humacyte in the 2nd quarter worth $49,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Price Performance

Shares of HUMA traded up $0.04 during midday trading on Monday, reaching $2.58. The stock had a trading volume of 1,721,209 shares, compared to its average volume of 3,829,739. The company's 50-day moving average is $2.20 and its 200 day moving average is $2.91. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.79. The company has a current ratio of 3.68, a quick ratio of 3.28 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $399.43 million, a price-to-earnings ratio of -3.73 and a beta of 1.89.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to analysts' expectations of $0.46 million. On average, equities analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.